By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
MESHAMESHAMESHA
  • Home
  • Who We Are
    • About
    • Management
    • Strategic Plan, 2023-2027
  • Sayansi Magazine
  • Media
    • Audio
    • Videos
    • Photos
  • Membership
    • Accredited Members
    • How to Join MESHA
  • IFAJ 2025 Congress
Search
Categories
  • Climate Change
  • Health
  • Biodiversity
  • Agriculture
  • Environment
© 2024 MESHA. All Rights Reserved.
Reading: No sufficient protection, findings say of HIV vaccine candidate
Share
Sign In
Notification Show More
Font ResizerAa
MESHAMESHA
Font ResizerAa
Search
  • Home
  • Who We Are
    • About
    • Management
    • Strategic Plan, 2023-2027
  • Sayansi Magazine
  • Media
    • Audio
    • Videos
    • Photos
  • Membership
    • Accredited Members
    • How to Join MESHA
  • IFAJ 2025 Congress
Have an existing account? Sign In
Follow US
© 2024 Mesha. All Rights Reserved.
MESHA > Blog > Health > No sufficient protection, findings say of HIV vaccine candidate
Health

No sufficient protection, findings say of HIV vaccine candidate

Mesha
Mesha Published 4 September 2021
Share
6 Min Read
SHARE

Results from Phase 2B of the Imbokodo Study – carried out to test the efficacy and safety of a HIV vaccine candidate among women in five sub-Saharan African countries – shows that the vaccine candidate does not provide sufficient protection against HIV.

The study was conducted among 2,600 plus women in 23 sites across South Africa, Zambia, Zimbabwe, Mozambique and Malawi among women aged 18- 35 years at risk of acquiring HIV.

Discussing the findings at a Media for Environment, Science, Health and Agriculture (MESHA) briefing, Mitchel Warren, Executive Director of AVAC said that the efficacy of the vaccine was found to be at 25 percent.

“There was some hint that the vaccine was working very partially,” he said, “ but it is not strong enough to warrant the vaccine continuing in this trial because it is not good enough to get it licensed.”

Also known as the HVTN705/HPX2008, the study involved participants getting four different doses over the first 12 months of their participation.

“The first two were called prime, based on a cold virus, Adenovirus26. Then they received further boost- protein booster- to help stimulate the immune system. Half of the women received this combination, while the other half received four shots of a placebo, that didn’t have any active ingredient,” Warren explained, adding that the women were followed for 24 months after the final shot.

The Imbokodo study found that through 24 months of follow up, 63 of 1,109 participants who received placebo compared to 51 of 1,079 participants who received active vaccine acquired HIV.

In addition, it found that despite the low efficacy, the vaccine was safe and there was no adverse event reported.

There is a parallel trial ongoing dubbed the Mosaico trial being carried out on 3,000 men who have sex with men and transgender individuals in Latin America, US and Europe. The study uses a similar regimen with the same Adenovirus26 platform for the prime vaccine, but using a different form of protein boost.

“It is possible the vaccine could work differently because it is a different boost, addressing a different route of HIV transmission (anal route) or because it is in a different part of the world with different circulating HIV,” Warren said.

According to Warren, the Imbokodo study is a stark reminder of the need to develop a HIV vaccine and the need to scale up prevention products that are already at hand such as the condoms, Oral PrEP, injectable PrEP and vaginal ring among others.

“We have to go all in for the prevention products we have. We have to roll them out with urgency so that people can protect themselves today while we reorient the HIV research agenda,” he said.

The HIV vaccine was being developed in a public-private partnership by Johnson and Johnson in collaboration with National Institutes of Health, the Bill & Melinda Gates Foundation, and the HIV Vaccine Trials Network (HVTN) among others.

“HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system,” Paul Stoffels, Managing Director, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson said in a statement
during the release of the study findings.

“While we are disappointed the vaccine candidate did not provide a sufficient level of protection against HIV infection in the Imbokodo trial, the study will give us important scientific findings in the ongoing pursuit for a vaccine to prevent HIV.

We continue to stand in solidarity with people living with and vulnerable to HIV, and remain committed to furthering our research against this devastating virus,” he added.

Though it has been 37 years of existing with HIV, developing a vaccine for the virus has been an arduous task mainly due to the HIV strain diversity and the immune evasion strategies of the virus.

According to Ronald C. Desrosiers, Professor of Pathology, Vice-Chair for Research, University of Miami, in an article, the development of the vaccine is made difficult by the biological properties of HIV. This includes the ability of the virus to continuously replicate, to generate and tolerate many mutations in its genetic information as well as the ability to shield itself from recognition by antibodies.

Besides the Imbokodo study, there have been five other trials to find a vaccine for HIV. All of them failed since there was no protection against acquisition of the virus or lowering of viral loads for those infected.

Currently, the PrEPVacc studies are ongoing in Africa- Uganda, Tanzania, Mozambique and South Africa- to test efficacy of a two experimental combination of HIV vaccine regimen while also comparing the effectiveness of a new form of oral PrEP (Descovy) against Truvada. The study which includes both men and women aged 18-40 years at risk of HIV
started in 2018 and will end in 2023.

 

By Sharon Atieno

You Might Also Like

African countries urged to keep vigilance on COVID-19

County of Bungoma launches 10-day campaign to upscale COVID-19 vaccination

The catch 22 situation in using HIV self-test kits

Aids conference opens in Munich with calls for more funding to boost response

MESHA hosts regional media symposium on climate change, HIV and pandemics

TAGGED:HIV vaccine

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Whatsapp Whatsapp LinkedIn Email Copy Link Print
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Options now available for women to reduce HIV risk
Next Article Scientists now testing vaginal ring that can prevent HIV and pregnancy
Ethics key as AI and social media redefine science reporting, journalists told
Uncategorised
MESHA gets boost to implement project on Africa-led climate stories
Climate
Presentations from MESHA’s Science Café: Framing Reproductive Health Stories Through Solutions Journalism and Lived Reporting Experiences
Solutions Journalism
Stakeholders out to tackle climate induced malaria surge at Kenya’s coast
Health

Contact Info

Location
Oasis Apartments, Jogoo Road, 3rd Floor
Phone
+254 721 578517
+254 732 229 230
info@meshascience.org

Facebook

//

We are the number one science, health and agriculture journalists network in Africa accessed by over 20 million users.

Quick Link

  • About
  • Sayansi Magazine
  • Accredited Members
  • Mesha Audio
  • My Bookmarks

Top Categories

  • Climate Change
  • Health
  • Biodiversity
  • Agriculture
  • Environment

Sign Up for Our Newsletter

Subscribe to our newsletter to get our newest articles instantly!

MESHAMESHA
Follow US
© 2024 MESHA. All Rights Reserved.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..

Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?